Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05352893 · ClinicalTrials.gov registry record · Phase 3
Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Subjects With GPP
A Phase 3 study, sponsored by Vanda Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 45
- Enrollment target
NCT05352893 is a Phase 3 study that has completed, run by Vanda Pharmaceuticals. The registered enrollment target is 45 participants.
The verdict
NCT05352893, a Phase 3 study, has completed, sponsored by Vanda Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 45 participants
- Enrollment target
Study Summary
This is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of imsidolimab compared with placebo in adult subjects with generalized pustular psoriasis (GPP).
Interventions
- OTHER Placebo
- DRUG 750 mg Imsidolimab
- DRUG 300 mg Imsidolimab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2022-04-14 |
| Est. Completion | 2023-08-17 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05352893
The ClinicalTrials.gov registry entry for NCT05352893 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vanda Pharmaceuticals, which has 68 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT05352893 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05352893 about?
NCT05352893 is a clinical study titled "Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Subjects With GPP". This is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of imsidolimab compared with placebo in adult subjects with generalized pustular psoriasis (GPP).
What is the current status of trial NCT05352893?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 45 participants. The study started on 2022-04-14. Estimated completion is 2023-08-17.
What interventions are being tested in trial NCT05352893?
The interventions under investigation include: Placebo (OTHER), 750 mg Imsidolimab (DRUG), 300 mg Imsidolimab (DRUG).
Who is sponsoring clinical trial NCT05352893?
This trial is sponsored by Vanda Pharmaceuticals, which has 68 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.